Prostate cancer is the 2^nd most common cancer in men and 5^th leading cause of death worldwide. The early line of therapy is focused on androgen deprivation, usually with the traditional ADTs or the NHTs (next-generation hormonal therapies). While the NHTs are approved across stages from nmCRPC, mHSPC to mCRPC. Currently, PARP with NHT combos and radioligand therapies are being developed in 1L mCRPC and mHSPC settings